Dragon boat team of breast cancer survivors celebrates 30 years in Vancouver
The Abreast In A Boat team was started by Vancouver doctor Don McKenzie in 1996 — initially as a six-month trial to show whether there was any evidence to back up a commonly held idea that was limiting the lives of breast cancer survivors.
At the time, the scientific consensus was that those who'd had a mastectomy shouldn't be raising their arms over their heads, lifting heavy objects or exercising.
Instead, the team demonstrated that not only was strenuous exercise possible for breast cancer survivors, but physical activity and a sense of belonging helped them in their recovery from cancer.
Ahead of the dragon boating festival, which starts June 20 in False Creek, members of the team told CBC News about how the team changed their lives.
'I could trust my body'
When Carol Dale signed up for the team in 1996, she was celebrating five years being cancer-free, and thought it was an interesting experiment worth trying.
"It just turned out to be a fascinating year, learning a new skill, learning that I could trust my body again to work for me," she said.
"And I met some wonderful people, and that's what keeps me going."
Dale says there are now six teams in the Lower Mainland alone composed of breast cancer survivors, and dozens more in Canada and around the world.
And, there's even an international commission encouraging the establishment of more dragon boat teams for those with breast cancer.
Recovery ideas change
Kristin Campbell, a professor at the University of British Columbia's department of physical therapy, says that when the team was first started in 1996, it was thought that repeated exercise would lead to lymphedema, a painful chronic condition where lymph fluid builds up in a person's arm due to being disrupted by the cancerous cells.
"The important piece about this dragon boat experience [is] how it's changed practice around the world," the researcher said.
"I think they really have shown that the role of exercise and the camaraderie, that you get from that, really changed how people thought about breast cancer, and thought about exercise and recovery after treatment," she added.
Dr. McKenzie's work, along with collaborators, helped demonstrate that regular physical activity is associated with a 35 per cent reduction in mortality among cancer survivors.
Breast cancer is the second most-common cancer in Canada, and roughly one in eight women are expected to be diagnosed with it in their lifetimes.
While some like Dale are veterans of the team, others like Anca Dobre, 29, are more recent competitors.
She was diagnosed in December 2023, and finished her radiation treatment the following August.
Dobre said that the team showed her that a diagnosis didn't necessarily mean she was going to be bedridden.
"Actually, it was the opposite," she told CBC News. "We all became more active.
"There's so much to life after cancer and it's not just about surviving, but actually thriving, with this team because they're all so inspirational in everything they do."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Raynaud Phenomenon Tied to Elevated Cardiovascular Risk
TOPLINE: Individuals with Raynaud phenomenon without underlying systemic autoimmune rheumatic diseases had higher risks for major adverse cardiovascular events (MACE) and venous thromboembolism than did a comparator group with irritable bowel syndrome (IBS), regardless of age. METHODOLOGY: Researchers conducted a retrospective cohort study to examine whether individuals with Raynaud phenomenon experienced cardiovascular outcomes more frequently than those without the condition. They included 30,088 individuals younger than 45 years and 60,145 aged 45 years or older with Raynaud phenomenon without systemic autoimmune rheumatic diseases , identified from electronic health records of centers in North America between March 2005 and March 2025. An equal number of propensity score-matched individuals with IBS were assigned as comparators to both age categories. The researchers chose IBS as a comparator group because, like Reynaud phenomenon, it is common in younger and female individuals. In addition, it is not known to be associated with adverse cardiovascular outcomes. Co-primary outcomes were MACE and venous thromboembolism, evaluated over mean follow-up durations of 4.4-4.9 years across groups. TAKEAWAY: Among individuals younger than 45 years, those with Raynaud phenomenon had higher risks for MACE (hazard ratio [HR], 1.23; 95% CI, 1.07-1.42) and venous thromboembolism (HR, 1.32; 95% CI, 1.20-1.46) than did those with IBS. Similar results were observed among individuals aged 45 years or older, where those with Raynaud phenomenon had higher risks for MACE (HR, 1.17; 95% CI, 1.13-1.20) and venous thromboembolism (HR, 1.20; 95% CI, 1.14-1.26) than those with IBS. Individuals with Raynaud phenomenon had higher risks for secondary outcomes such as stroke, any cardiovascular disease, and pulmonary embolism noted in both age categories. IN PRACTICE: '[This] data substantiates several previous reports of an increased risk of CVD [cardiovascular disease] in individuals with RP [Raynaud phenomenon], and provides further supporting evidence of a similar risk of VTE [venous thromboembolism],' the authors of the study wrote. 'Taken together our findings lend further support to suggest that RP (in the absence of any secondary SARD [systemic autoimmune rheumatic disease]) could be a manifestation of subclinical CVD. Of course, this requires further confirmation including prospective studies,' they added. SOURCE: This study was led by Michael Hughes, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. It was published online on August 5, 2025, in Seminars in Arthritis and Rheumatism. LIMITATIONS: Diagnostic codes were used for identifying the conditions; however, misclassification bias may be possible. Details such as digital ischemic episodes were not available for individuals with Raynaud phenomenon and age of onset and family history were not assessed. Many oral drug treatments for Raynaud phenomenon are vasodilators also used for systemic hypertension; hence, the primary indication was unclear. DISCLOSURES: One author reported receiving support from the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Another author reported receiving support from NIHR Clinical Lectureship, and working at centers supported by Versus Arthritis and NIHR Manchester Biomedical Research Centre. Two authors reported receiving research funding, speaker fees, honoraria, and consultancy fees and having other financial ties with multiple companies including Janssen, Sanofi, and Novartis. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
AI-powered brain implant restores speech in paralysis patient after 18 years
Eighteen years after a brainstem stroke left her with near-total paralysis, Ann Johnson heard her voice again, thanks to a brain-computer interface (BCI) that decodes speech directly from brain activity. Johnson, then 30, was a high school teacher and coach in Saskatchewan, Canada, when the 2005 stroke caused locked-in syndrome, a rare condition in which a person remains conscious but unable to speak or move. Since then, she has communicated using an eye-tracking system at just 14 words per minute, a far from natural conversational speed of about 160 words per minute. In 2022, she became the third participant in a clinical trial led by researchers at the University of California, Berkeley, and UC San Francisco aimed at restoring speech for people with severe paralysis. The team used a neuroprosthesis that records signals from the speech motor cortex, bypassing damaged neural pathways to produce audible words. Turning thought into voice The device relies on an implant placed over the brain's speech production area. When Johnson attempts to speak, the implant detects neural activity and sends the signals to a connected computer. An AI decoder then translates these signals into text, speech, or facial animation on a digital avatar. Originally, the system used sequence-to-sequence AI models that required an entire sentence before producing output, creating an eight-second delay. In March 2025, the team reported in Nature Neuroscience that they had switched to a streaming architecture, allowing near-real-time translation with just a one-second delay. To personalize the experience, researchers recreated Johnson's voice from a recording of her 2004 wedding speech. She also selected an avatar to match her appearance, which can mimic facial expressions such as smiling or frowning. Engineering for everyday use Lead researchers Assistant Professor of Electrical Engineering and Computer Sciences Gopala Anumanchipalli (UC Berkeley), neurosurgeon Edward Chang (UCSF), and Berkeley Ph.D. student Kaylo Littlejohn say the goal is to make neuroprostheses 'plug-and-play,' turning them from experimental systems into standard clinical tools. Future improvements could include wireless implants, eliminating the need for direct computer connections, and photorealistic avatars for more natural interactions. The team envisions digital 'clones' that replicate not just a user's voice but also their conversational style and visual cues. The breakthrough could help a relatively small but highly vulnerable population, including people who lose the ability to speak due to stroke, ALS, or injury, reclaim faster, more natural communication. Researchers emphasize that the system only works when the participant intentionally tries to speak, preserving user agency and privacy. For Johnson, the trial was life-changing. 'I want patients to see me and to know their lives are not over now,' she said in a statement to UCSF. She hopes to one day work as a counselor in a rehabilitation center, using a neuroprosthesis to talk with clients. With latency down to about a second and ongoing advances in AI modeling, the researchers believe practical, real-time speech restoration could arrive within just a few years, reshaping how technology gives voice to those who have lost their own. Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Target-owned brand of frosted sugar cookies recalled due to possible contamination with wood pieces
So far, no illnesses have been reported. Frosted sugar cookies sold at Target stores across the United States have been recalled because they may contain pieces of wood. The U.S. Food and Drug Administration issued a recall for 803 cases of Favorite Day Bakery frosted sugar cookies sold at Target stores in 20 states and Washington, D.C. Favorite Day is a private label brand sold at Target. The voluntary recall was initiated on July 22, 2025, by Give and Go Prepared Foods Corp in Etobicoke, Canada, which prepared the affected bakery items. As of Aug. 13, Target does not have the recall listed on its website. How can I identify which specific cookies are recalled? The affected Favorite Day Bakery frosted sugar cookies are the 10-count packages (Net wt. 13.5 oz.) with lot number 25195 and UPC code 85239-41250 3. 'Best By Date can vary as they are applied by retailer when removed from freezer,' the FDA indicates in the recall. Has anyone gotten sick from the cookies? No illnesses have been reported yet. However, the FDA classified the recall as Class II, which means eating the contaminated cookies 'may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' Where are the Target stores that sold the affected cookies? The FDA says the affected cookies were distributed to Target stores in the following states and D.C.: Connecticut Delaware Illinois Indiana Kentucky Maine Maryland Massachusetts Michigan Missouri New Hampshire New Jersey New York North Carolina Ohio Pennsylvania Rhode Island Tennessee Vermont Virginia Washington, D.C. I bought the cookies that were recalled. What should I do? Customers who purchased the affected frosted sugar cookies can get a full refund by bringing them to their nearest Target store or by calling Target guest relations at 1-800-440-0680. Solve the daily Crossword
